Published in Biochem Biophys Res Commun on January 26, 2001
GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci (2003) 10.89
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Genetics of circadian rhythms in Mammalian model organisms. Adv Genet (2011) 2.80
Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol (2009) 2.77
Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology (2010) 1.87
Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J Biol Chem (2007) 1.86
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem (2008) 1.64
Two putative BIN2 substrates are nuclear components of brassinosteroid signaling. Plant Physiol (2002) 1.64
The role of GSK-3 in synaptic plasticity. Br J Pharmacol (2008) 1.52
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Inhibition of glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied hearts. Ann Thorac Surg (2007) 1.44
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans (2009) 1.27
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol Neurodegener (2008) 1.20
Lithium impacts on the amplitude and period of the molecular circadian clockwork. PLoS One (2012) 1.14
Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci (2012) 1.14
Natural products as a source of Alzheimer's drug leads. Nat Prod Rep (2010) 1.13
Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence. Mol Cell Biol (2004) 1.13
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci (2012) 1.12
Glycogen synthase kinase-3beta (GSK3beta) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Mol Immunol (2008) 1.11
β-catenin/Wnt signaling controls progenitor fate in the developing and regenerating zebrafish retina. Neural Dev (2012) 1.11
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem (2004) 1.09
Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J Circadian Rhythms (2007) 1.01
Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis (2012) 0.99
Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci (2014) 0.98
Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci (2007) 0.98
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Glycogen synthase kinase-3 is required for efficient Dictyostelium chemotaxis. Mol Biol Cell (2010) 0.94
Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav (2014) 0.94
Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin (2011) 0.93
Growing the growth cone: remodeling the cytoskeleton to promote axon regeneration. Trends Neurosci (2011) 0.93
Effects of GSK3 inhibitors on in vitro expansion and differentiation of human adipose-derived stem cells into adipocytes. BMC Cell Biol (2008) 0.93
Mood stabilizer psychopharmacology. Clin Neurosci Res (2002) 0.93
Stabilisation of β-catenin downstream of T cell receptor signalling. PLoS One (2010) 0.93
Convergence of 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A and glycogen synthase kinase-3beta/beta-catenin signaling in corpus luteum progesterone synthesis. Endocrinology (2009) 0.93
Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes. Expert Opin Ther Targets (2008) 0.92
JCV agnoprotein-induced reduction in CXCL5/LIX secretion by oligodendrocytes is associated with activation of apoptotic signaling in neurons. J Cell Physiol (2012) 0.92
NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest (2010) 0.92
Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2). J Cell Physiol (2012) 0.92
Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol (2013) 0.91
Glycogen synthase kinase-3 regulation of urinary concentrating ability. Curr Opin Nephrol Hypertens (2012) 0.89
The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol (Los Angel) (2013) 0.88
Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr Scand (2012) 0.87
The polyketide MPBD initiates the SDF-1 signaling cascade that coordinates terminal differentiation in Dictyostelium. Eukaryot Cell (2011) 0.87
Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer. Int J Mol Sci (2013) 0.86
Enhanced endothelial cell senescence by lithium-induced matrix metalloproteinase-1 expression. J Biol Chem (2009) 0.86
Lithium and genetic inhibition of GSK3beta enhance the effect of methamphetamine on circadian rhythms in the mouse. Behav Pharmacol (2009) 0.85
Nutritional limitation sensitizes mammalian cells to GSK-3β inhibitors and leads to growth impairment. Am J Pathol (2011) 0.84
Advances in tau-based drug discovery. Expert Opin Drug Discov (2011) 0.83
Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol (2013) 0.83
Functional role of inorganic trace elements in angiogenesis part III: (Ti, Li, Ce, As, Hg, Va, Nb and Pb). Crit Rev Oncol Hematol (2015) 0.83
Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats. Front Behav Neurosci (2014) 0.82
Unlocking mechanisms in interleukin-1β-induced changes in hippocampal neurogenesis--a role for GSK-3β and TLX. Transl Psychiatry (2012) 0.82
Lithium and autophagy. ACS Chem Neurosci (2014) 0.82
Glycogen synthase kinase-3: A potential preventive target for prostate cancer management. Urol Oncol (2015) 0.82
A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist (2011) 0.82
Inositol synthesis regulates the activation of GSK-3α in neuronal cells. J Neurochem (2014) 0.81
Glycogen synthase kinase 3α regulates urine concentrating mechanism in mice. Am J Physiol Renal Physiol (2015) 0.81
Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer. Int J Gynecol Cancer (2013) 0.80
Lithium's gene expression profile, relevance to neuroprotection A cDNA microarray study. Cell Mol Neurobiol (2013) 0.80
Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia. Dialogues Clin Neurosci (2006) 0.79
Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology. Neuropharmacology (2009) 0.79
Altered regulation of Akt signaling with murine cerebral malaria, effects on long-term neuro-cognitive function, restoration with lithium treatment. PLoS One (2012) 0.79
Potential molecular and cellular mechanism of psychotropic drugs. Clin Psychopharmacol Neurosci (2014) 0.79
Prolyl oligopeptidase, inositol phosphate signalling and lithium sensitivity. CNS Neurol Disord Drug Targets (2011) 0.78
GSK-3 activity is critical for the orientation of the cortical microtubules and the dorsoventral axis determination in zebrafish embryos. PLoS One (2012) 0.78
Lithium's role in neural plasticity and its implications for mood disorders. Acta Psychiatr Scand (2013) 0.78
Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus. J Neural Transm (Vienna) (2006) 0.78
Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons. Brain Res (2012) 0.78
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res (2009) 0.77
Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plast (2015) 0.77
Differential display RT-PCR reveals genes associated with lithium-induced neuritogenesis in SK-N-MC cells. Cell Mol Neurobiol (2011) 0.76
Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas. Oncogene (2016) 0.76
GSK-3β inhibition protects mesothelial cells during experimental peritoneal dialysis through upregulation of the heat shock response. Cell Stress Chaperones (2013) 0.76
Akt Phosphorylates Wnt Coactivator and Chromatin Effector Pygo2 at Serine 48 to Antagonize Its Ubiquitin/Proteasome-mediated Degradation. J Biol Chem (2015) 0.76
Estradiol and lithium chloride specifically alter NMDA receptor subunit NR1 mRNA and excitotoxicity in primary cultures. Brain Res (2009) 0.76
Solid lipid nanoparticles regulate functional assortment of mouse mesenchymal stem cells. J Stem Cells Regen Med (2011) 0.75
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease. PLoS Genet (2017) 0.75
Gsk-3β inhibitors mimic the cardioprotection mediated by ischemic pre- and postconditioning in hypertensive rats. Biomed Res Int (2013) 0.75
Rapid Detection of Glycogen Synthase Kinase-3 Activity in Mouse Sperm Using Fluorescent Gel Shift Electrophoresis. Sensors (Basel) (2016) 0.75
Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism. Physiol Rep (2016) 0.75
Inhibition of all-trans retinoic acid-induced granulocytic differentiation of WEHI-3B D+ cells by forced expression of SCL (TAL1) and GATA-1. Leuk Res (2009) 0.75
Protective effect of pretreatment with propofol against tumor necrosis factor-α-induced hepatic insulin resistance. Exp Ther Med (2015) 0.75
Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. BMC Med (2012) 0.75
Lithium increases synaptic GluA2 in hippocampal neurons by elevating the δ-catenin protein. Neuropharmacology (2016) 0.75
A fully integrated new paradigm for lithium's mode of action - lithium utilizes latent cellular fail-safe mechanisms. Neuropsychiatr Dis Treat (2017) 0.75
Chromosome territory relocation during DNA repair requires nuclear myosin 1 recruitment to chromatin mediated by ϒ-H2AX signaling. Nucleic Acids Res (2016) 0.75
Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genomics Proteomics (2010) 0.75
The effect of Li+ on GSK-3 inhibition: molecular dynamics simulation. J Mol Model (2010) 0.75
Antifibrotic Actions of Peroxisome Proliferator-Activated Receptor γ Ligands in Corneal Fibroblasts Are Mediated by β-Catenin-Regulated Pathways. Am J Pathol (2017) 0.75
MCK1 is a novel regulator of myo-inositol phosphate synthase (MIPS) that is required for inhibition of inositol synthesis by the mood stabilizer valproate. PLoS One (2017) 0.75
Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. PLoS One (2017) 0.75
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
An intersection of the cAMP/PKA and two-component signal transduction systems in Dictyostelium. EMBO J (1998) 1.57
Adherens junctions and beta-catenin-mediated cell signalling in a non-metazoan organism. Nature (2000) 1.45
Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J (1999) 1.41
Activation of the prespore and spore cell pathway of Dictyostelium differentiation by cAMP-dependent protein kinase and evidence for its upstream regulation by ammonia. EMBO J (1993) 1.28
An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts. Anal Biochem (1998) 1.26
Glycogen synthase kinase-3 (GSK-3) is regulated during Dictyostelium development via the serpentine receptor cAR3. Development (1999) 1.22
Lithium therapy and signal transduction. Trends Pharmacol Sci (2000) 1.10
Glycogen synthase kinase-3 enhances nuclear export of a Dictyostelium STAT protein. EMBO J (2000) 1.08
The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol Pharmacol (2006) 1.06
Cell-cell adhesion and signal transduction during Dictyostelium development. J Cell Sci (2001) 1.03
A molecular cell biology of lithium. Biochem Soc Trans (2004) 0.86
Regulation of Dictyostelium morphogenesis by cAMP-dependent protein kinase. Philos Trans R Soc Lond B Biol Sci (1993) 0.79
'Super glue'. Nat Cell Biol (2001) 0.76
Signal transduction and Dictyostelium development. Protist (2001) 0.76
A novel, negative selectable marker for gene disruption in Dictyostelium. Gene (1997) 0.76
Screening lambda libraries. Methods Mol Biol (1996) 0.75
Modeling psychiatric disorders: from genomic findings to cellular phenotypes. Mol Psychiatry (2016) 0.75